Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06609213 · ClinicalTrials.gov registry record · NA

Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS

A NA study of Amyotrophic Lateral Sclerosis and Gastrointestinal Intolerance, sponsored by Andrea Charvet.

Recruiting
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT06609213: Recruiting NA study of Amyotrophic Lateral Sclerosis and Gastrointestinal Intolerance, sponsored by Andrea Charvet.

NCT06609213 is a NA study of Amyotrophic Lateral Sclerosis and Gastrointestinal Intolerance that is actively recruiting participants, run by Andrea Charvet. The registered enrollment target is 22 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06609213, a NA study of Amyotrophic Lateral Sclerosis and Gastrointestinal Intolerance, is actively recruiting participants, sponsored by Andrea Charvet.

RECRUITING
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The main objective of the proposed study is to evaluate if oral intake of EN formula preceding Gtube placement will impact tolerance upon placement and feeding via Gtube in pALS. This single arm intervention study all participants will receive the intervention and researchers will utilize validated indicators combined with clinical expertise to assess gastrointestinal symptoms of feeding intolerance before and after the intervention. The main questions this study aims to answer are: 1. Wil participants meeting a greater percentage of their estimated nutritional needs at baseline present a slower disease progression rate and a lower incidence of GI symptoms of feeding intolerance when feeding via Gtube? 2. Will there be significant change in feeding intolerance when oral intake of enteral nutrition formula precedes feeding via Gtube? This proposed study consists of three stages, as follows: 1. Pre-Intervention: The lead in period of one-week preceding intervention phase I will be timed to initiate 3 weeks before the scheduled Gtube placement procedure. Patients will be advised to maintain their usual food and beverage intake. Dietary intake and GI symptoms data will be collected by research personnel. 2. Phase I: Dietary intake data collected from the pre-intervention stage will be averaged and used to determine the number of cartons of enteral nutrition formula needed to meet the participants estimated nutritional needs. For two weeks +- 2 days participants will be directed to drink the number of cartons of a pre-selected enteral nutrition formula to meet their estimated nutritional needs when combined to their current oral dietary intake. A plant based EN formula (Kate Farms 1.4 Standard) commonly prescribed for pALS was selected to be provided to all patients in the study to keep this variable constant. Weekly data collection of dietary intake and GI symptoms will be ongoing. 3. Phase II: At the end of phase I, patients will undergo a Gtube placement at their

Primary Outcome

Gastrointestinal symptoms of feeding intolerance will be monitored weekly using a clinician-administered survey in-person or via phone interview. The Gastrointestinal Symptom Rating Scale (GSRS) is a 15-item scale that combines each item into five symptom clusters including reflux, abdominal pain, indigestion, diarrhea, and constipation (Svedlund et al., 1988). Patients rate each item on a 7-point Likert scale (from no discomfort at all to very severe discomfort).

Interventions

  • OTHER Medical Food

Study Locations (1)

Florida

  • Nova Southeastern University, Cathy J, Husman ALS Center - Fort Lauderdale

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2025-01-10
Est. Completion 2026-06
Phase NA
Andrea Charvet

1 total trials

What NCT06609213 shows while recruiting

NCT06609213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Medical Food is the first listed.

NCT06609213 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06609213 about?

NCT06609213 is a clinical study titled "Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS". The main objective of the proposed study is to evaluate if oral intake of EN formula preceding Gtube placement will impact tolerance upon placement and feeding via Gtube in pALS. This single arm intervention study all participants will receive the intervention and researchers will utilize validated ...

What is the current status of trial NCT06609213?

This trial is currently recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2025-01-10. Estimated completion is 2026-06.

What conditions does trial NCT06609213 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance, Enteral Nutrition Therapy.

What interventions are being tested in trial NCT06609213?

The interventions under investigation include: Medical Food (OTHER).

Who is sponsoring clinical trial NCT06609213?

This trial is sponsored by Andrea Charvet, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06609213 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06609213's enrollment target sits among peer trials

22 75th of 102 higher than 27 of 102 other Amyotrophic Lateral Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06609213, the US trial registry maintained by the National Library of Medicine. NCT06609213 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.